Defining optimal combinations of PI3K/Akt/mTOR and Ras/Raf/MAPK pathway inhibitors for use in endometrial cancer

Authors :: Alicia Rodriguez-Gabin
Sara Isani
Hayley M. McDaid
Susan Band Horwitz
Gary L. Goldberg
Source :: Gynecologic Oncology. 133:127-128
Publication Year :: 2014
Publisher :: Elsevier BV, 2014.

Subjects :: MAPK/ERK pathway
Oncology
business.industry
Endometrial cancer
Anti-apoptotic Ras signalling cascade
RPTOR
Cancer research
Obstetrics and Gynecology
Medicine
business
medicine.disease
Protein kinase B
PI3K/AKT/mTOR pathway

Full Text Access

Tools